Navigation Links
Poniard Pharmaceuticals to Present at the 8th Annual Needham Life Sciences Conference
Date:6/5/2009

SOUTH SAN FRANCISCO, Calif., June 5 /PRNewswire-FirstCall/ -- Poniard Pharmaceuticals, Inc. (Nasdaq: PARD), a biopharmaceutical company focused on innovative oncology therapies, today announced that Jerry McMahon, Ph.D., chairman and chief executive officer, will provide a corporate overview at the 8th Annual Needham Life Sciences Conference on Wednesday, June 10 at 2:30 p.m. Eastern Time in New York.

Dr. McMahon's corporate presentation will include a discussion about the clinical development program for the Company's lead product candidate, picoplatin.

A live audio webcast of the corporate overview will be available for 10 business days on the "Events" page of the "News & Events" section of the Company's Web site at http://www.poniard.com.

About Poniard Pharmaceuticals

Poniard Pharmaceuticals, Inc. is a biopharmaceutical company focused on the development and commercialization of innovative oncology products to impact the lives of people with cancer. Picoplatin, the Company's lead platform product candidate, is a new generation platinum chemotherapy. To date, clinical studies suggest that picoplatin has an improved safety profile relative to existing platinum-based cancer therapies. Picoplatin is designed to overcome platinum resistance associated with chemotherapy in solid tumors, and is being studied in multiple cancer indications, combinations and formulations. Clinical trials of intravenous picoplatin include a Phase 3 trial in small cell lung cancer and Phase 2 trials in metastatic colorectal and castration-resistant (hormone refractory) prostate cancers. The Company also is conducting a clinical trial of oral picoplatin in solid tumors. For additional information please visit http://www.poniard.com.

(C) 2009 Poniard Pharmaceuticals, Inc. All Rights Reserved.

Poniard and Poniard Pharmaceuticals are trademarks of Poniard Pharmaceuticals, Inc.


'/>"/>
SOURCE Poniard Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Poniard Pharmaceuticals Files Shelf Registration
2. Poniard Pharmaceuticals to Present at the Leerink Swann Oncology Roundtable Conference
3. Poniard Pharmaceuticals to Present at the 2009 BIO International Convention
4. Poniard Pharmaceuticals Presents Final Results of Phase 1 Study of Picoplatin in Patients with Metastatic Colorectal Cancer
5. Poniard Pharmaceuticals to Present Final Data from Picoplatin Phase 1 Clinical Trials at American Association for Cancer Researchs 100th Annual Meeting
6. Poniard Pharmaceuticals Reschedules Fourth Quarter and Fiscal 2008 Results Conference Call for Monday, March 16
7. Poniard Pharmaceuticals to Host Fourth Quarter and Year-End 2008 Financial Results Conference Call on March 12
8. Poniard Pharmaceuticals Announces New Efficacy and Safety Data from a Phase 2 Picoplatin Trial in Patients with Prostate Cancer
9. Poniard Pharmaceuticals to Present at the BIO CEO & Investor Conference
10. Poniard Pharmaceuticals Announces Positive Tumor Response and Neuropathy Data from Phase 2 Clinical Trial of Picoplatin in Metastatic Colorectal Cancer
11. Poniard Pharmaceuticals to Present Data from Phase 2 Clinical Trials of Picoplatin in Colorectal and Prostate Cancers
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/22/2017)... PA (PRWEB) , ... June 22, 2017 , ... ... and superior results to clients throughout the biopharma and life sciences industries, continue ... the industry is seeing. Tunnell’s Kip Wolf will be speaking on “The State ...
(Date:6/22/2017)... ... June 22, 2017 , ... Charm Sciences, Inc. is pleased ... test was determined to be appropriate as a screening test at dairies and farms ... Charm EZ system, and the Charm EZ Lite system. These systems are a combination ...
(Date:6/20/2017)... ... June 20, 2017 , ... ... the adulterants which pose the most likely threat to their products at the ... year. , IFT's annual food expo attracts over 20,000 attendees representing food ...
(Date:6/20/2017)... ... June 20, 2017 , ... Do More with OHAUS , ... being a trusted supplier in the weighing industry, to extending its expertise across the ... enzyme reactions, immunoassays, hybridizations and more, allowing for its customers to 'Do ...
Breaking Biology Technology:
(Date:4/4/2017)... , April 4, 2017   EyeLock LLC , ... that the United States Patent and Trademark Office (USPTO) ... covers the linking of an iris image with a ... and represents the company,s 45 th issued patent. ... is very timely given the multi-modal biometric capabilities that ...
(Date:3/29/2017)... -- higi, the health IT company that operates the largest ... , today announced a Series B investment from BlueCross ... new investment and acquisition accelerates higi,s strategy to create ... health activities through the collection and workflow integration of ... and secures data today on behalf of over 36 ...
(Date:3/23/2017)... March 23, 2017 The report "Gesture Recognition and Touchless ... and Geography - Global Forecast to 2022", published by MarketsandMarkets, the market is ... of 29.63% between 2017 and 2022. Continue Reading ... ... ...
Breaking Biology News(10 mins):